256 related articles for article (PubMed ID: 25786915)
41. Development of a Multivalent Kunjin Virus Reporter Virus-Like Particle System Inducing Seroconversion for Ebola and West Nile Virus Proteins in Mice.
Tran PT; Asghar N; Höglund U; Larsson O; Haag L; Mirazimi A; Johansson M; Melik W
Microorganisms; 2020 Nov; 8(12):. PubMed ID: 33260425
[TBL] [Abstract][Full Text] [Related]
42. Interplay of Ebola Virus With Immune Cells Leading to Their Death by Diverse Mechanisms.
Iampietro M; Amurri L; Reynard O; Bukreyev A
J Infect Dis; 2023 Nov; 228(Suppl 7):S582-S586. PubMed ID: 37654044
[TBL] [Abstract][Full Text] [Related]
43. Novel Antiviral Molecules against Ebola Virus Infection.
Collados Rodríguez M; Maillard P; Journeaux A; Komarova AV; Najburg V; David RS; Helynck O; Guo M; Zhong J; Baize S; Tangy F; Jacob Y; Munier-Lehmann H; Meurs EF
Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834238
[TBL] [Abstract][Full Text] [Related]
44. Spatial and functional arrangement of Ebola virus polymerase inside phase-separated viral factories.
Fang J; Castillon G; Phan S; McArdle S; Hariharan C; Adams A; Ellisman MH; Deniz AA; Saphire EO
Nat Commun; 2023 Jul; 14(1):4159. PubMed ID: 37443171
[TBL] [Abstract][Full Text] [Related]
45. Single virus tracking of Ebola virus entry through lipid rafts in living host cells.
Jin C; Che B; Guo Z; Li C; Liu Y; Wu W; Wang S; Li D; Cui Z; Liang M
Biosaf Health; 2020 Mar; 2(1):25-31. PubMed ID: 32835208
[TBL] [Abstract][Full Text] [Related]
46. Human Ebola virus infection in West Africa: a review of available therapeutic agents that target different steps of the life cycle of Ebola virus.
Lai KY; Ng WY; Cheng FF
Infect Dis Poverty; 2014; 3():43. PubMed ID: 25699183
[TBL] [Abstract][Full Text] [Related]
47. Identification and Potential Roles of Human MicroRNAs in Ebola Virus Infection and Disease Pathogenesis.
Mensah-Bonsu M; Doss C; Gloster C; Muganda P
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674337
[TBL] [Abstract][Full Text] [Related]
48. Informing the Historical Record of Experimental Nonhuman Primate Infections with Ebola Virus: Genomic Characterization of USAMRIID Ebola Virus/H.sapiens-tc/COD/1995/Kikwit-9510621 Challenge Stock "R4368" and Its Replacement "R4415".
Kugelman JR; Rossi CA; Wiley MR; Ladner JT; Nagle ER; Pfeffer BP; Garcia K; Prieto K; Wada J; Kuhn JH; Palacios G
PLoS One; 2016; 11(3):e0150919. PubMed ID: 27002733
[TBL] [Abstract][Full Text] [Related]
49. The Mechanism of Budding of Retroviruses From Cell Membranes.
Pincetic A; Leis J
Adv Virol; 2009 Jan; 2009():6239691-6239699. PubMed ID: 19865606
[TBL] [Abstract][Full Text] [Related]
50. Mapping of susceptibility loci for Ebola virus pathogenesis in mice.
Schäfer A; Marzi A; Furuyama W; Catanzaro NJ; Nguyen C; Haddock E; Feldmann F; Meade-White K; Thomas T; Hubbard ML; Gully KL; Leist SR; Hock P; Bell TA; De la Cruz GE; Midkiff BR; Martinez DR; Shaw GD; Miller DR; Vernon MJ; Graham RL; Cowley DO; Montgomery SA; Schughart K; de Villena FPM; Wilkerson GK; Ferris MT; Feldmann H; Baric RS
Cell Rep; 2024 May; 43(5):114127. PubMed ID: 38652660
[TBL] [Abstract][Full Text] [Related]
51. Recombinant Antibodies to the Ebola Virus Glycoprotein.
Panina AA; Dementieva IG; Aliev TK; Toporova VA; Balabashin DS; Bokov MN; Pozdnyakova LP; Shchemchukova OB; Dolgikh DA; Sveshnikov PG; Kirpichnikov MP
Acta Naturae; 2017; 9(4):84-91. PubMed ID: 29340221
[TBL] [Abstract][Full Text] [Related]
52. High-efficiency genetic engineering toolkit for virus based on lambda red-mediated recombination.
Yi J; Zhang M; Zhu L; Xu C; Li B; Wu P; Wu H; Zhang B
Biotechnol Lett; 2023 Oct; 45(10):1327-1337. PubMed ID: 37526868
[TBL] [Abstract][Full Text] [Related]
53. Exploring host-virus interaction to improve immunotherapy against Ebola virus.
Kasumba DM; Misasi J; Mulangu S; Mbala-Kingebeni P
Trends Pharmacol Sci; 2023 Dec; 44(12):857-861. PubMed ID: 37845170
[TBL] [Abstract][Full Text] [Related]
54. The Matrix protein M1 from influenza C virus induces tubular membrane invaginations in an in vitro cell membrane model.
Saletti D; Radzimanowski J; Effantin G; Midtvedt D; Mangenot S; Weissenhorn W; Bassereau P; Bally M
Sci Rep; 2017 Jan; 7():40801. PubMed ID: 28120862
[TBL] [Abstract][Full Text] [Related]
55. Phage display identification of high-affinity ligands for human TSG101-UEV: A structural and thermodynamic study of PTAP recognition.
Murciano-Calles J; Rodríguez-Martínez A; Palencia A; Andújar-Sánchez M; Iglesias-Bexiga M; Corbi-Verge C; Buzón P; Ruiz-Sanz J; Martínez JC; Pérez-Sánchez H; Cámara-Artigas A; Luque I
Int J Biol Macromol; 2024 Jun; 274(Pt 1):133233. PubMed ID: 38901510
[TBL] [Abstract][Full Text] [Related]
56. Curcumin and Natural Derivatives Inhibit Ebola Viral Proteins: An
Baikerikar S
Pharmacognosy Res; 2017 Dec; 9(Suppl 1):S15-S22. PubMed ID: 29333037
[TBL] [Abstract][Full Text] [Related]
57. Differences in Viral RNA Synthesis but Not Budding or Entry Contribute to the In Vitro Attenuation of Reston Virus Compared to Ebola Virus.
Bodmer BS; Greßler J; Schmidt ML; Holzerland J; Brandt J; Braun S; Groseth A; Hoenen T
Microorganisms; 2020 Aug; 8(8):. PubMed ID: 32796523
[TBL] [Abstract][Full Text] [Related]
58. SARS-CoV-2 Cellular Infection and Therapeutic Opportunities: Lessons Learned from Ebola Virus.
Muñoz-Basagoiti J; Perez-Zsolt D; Carrillo J; Blanco J; Clotet B; Izquierdo-Useros N
Membranes (Basel); 2021 Jan; 11(1):. PubMed ID: 33477477
[TBL] [Abstract][Full Text] [Related]
59. Navigating the Complex Landscape of Ebola Infection Treatment: A Review of Emerging Pharmacological Approaches.
Almeida-Pinto F; Pinto R; Rocha J
Infect Dis Ther; 2024 Jan; 13(1):21-55. PubMed ID: 38240994
[TBL] [Abstract][Full Text] [Related]
60. Homologous and heterologous protection of nonhuman primates by Ebola and Sudan virus-like particles.
Warfield KL; Dye JM; Wells JB; Unfer RC; Holtsberg FW; Shulenin S; Vu H; Swenson DL; Bavari S; Aman MJ
PLoS One; 2015; 10(3):e0118881. PubMed ID: 25793502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
